{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:43:43Z","timestamp":1788587023136,"version":"build-2803163510"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.canlet.2024.217272","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T02:26:36Z","timestamp":1727144796000},"page":"217272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Cellular dynamics of tumor microenvironment driving immunotherapy resistance in non-small-cell lung carcinoma"],"prefix":"10.1016","volume":"604","author":[{"given":"Shujie","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff Yat-Fai","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guibin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-Fai","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Ming-Kuen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.217272_bib1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.canlet.2024.217272_bib2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.canlet.2024.217272_bib3","article-title":"Osimertinib in resected EGFR-Mutated non-small-cell lung cancer","volume":"383","author":"Yl","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.217272_bib4","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Tsk","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.canlet.2024.217272_bib5","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Yl","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2024.217272_bib6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jtho.2018.08.004","article-title":"24-Month overall survival from KEYNOTE-021 Cohort G: Pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non\u2013small cell lung cancer","volume":"14","author":"Borghaei","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2024.217272_bib7","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial","volume":"17","author":"Ren","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2024.217272_bib8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non\u2013small-cell lung cancer: a phase 3 randomized clinical trial","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2024.217272_bib9","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41591-019-0639-4","article-title":"Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy","volume":"25","author":"Chowell","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.canlet.2024.217272_bib10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41586-021-03752-4","article-title":"Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers","volume":"596","author":"Caushi","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.217272_bib11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12943-021-01448-x","article-title":"Cancer cell-derived exosomal circUSP7 induces CD8+ T cell dysfunction and anti-PD1 resistance by regulating the miR-934\/SHP2 axis in NSCLC","volume":"20","author":"Chen","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2024.217272_bib12","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.217272_bib13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2024.217272_bib14","article-title":"Immunotherapy resistance in non-small-cell lung cancer: from mechanism to clinical strategies","volume":"14","author":"Zhou","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.217272_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.817548","article-title":"The landscape of immunotherapy resistance in NSCLC","volume":"12","author":"Frisone","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.217272_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100715","article-title":"Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance","volume":"53","author":"Erin","year":"2020","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.canlet.2024.217272_bib17","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/3046379","article-title":"The interplay between MicroRNAs and cellular components of tumour microenvironment (TME) on non-small-cell lung cancer (NSCLC) progression","volume":"2019","author":"Lee","year":"2019","journal-title":"J Immunol Res"},{"key":"10.1016\/j.canlet.2024.217272_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114319","article-title":"Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy","volume":"186","author":"Zhang","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.canlet.2024.217272_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004863","article-title":"Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects","volume":"10","author":"Peters","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2024.217272_bib20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12943-020-01260-z","article-title":"Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook","volume":"19","author":"Horvath","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2024.217272_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.811867","article-title":"TNF-\u03b1-Secreting lung tumor-infiltrated monocytes play a pivotal role during anti-PD-L1 immunotherapy","volume":"13","author":"De Ridder","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.217272_bib22","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/s41590-022-01224-z","article-title":"Epigenetic regulation of T cell exhaustion","volume":"23","author":"Belk","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2024.217272_bib23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2024.217272_bib24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2174\/1566524022666220610094716","article-title":"CTLA-4: as an immunosuppressive immune checkpoint in breast cancer","volume":"23","author":"Ghahremani Dehbokri","year":"2023","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.canlet.2024.217272_bib25","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2024.217272_bib26","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1038\/s41467-020-18298-8","article-title":"Collagen promotes anti-PD-1\/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion","volume":"11","author":"Peng","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.217272_bib27","article-title":"The identification of genes associated T-cell exhaustion and construction of prognostic signature to predict immunotherapy response in lung adenocarcinoma","volume":"13","author":"Wu","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2024.217272_bib28","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1038\/s41467-023-40745-5","article-title":"Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype","volume":"14","author":"Hiltbrunner","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.217272_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002780","article-title":"Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer","volume":"9","author":"Kim","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2024.217272_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add1016","article-title":"Multiomics and spatial mapping characterizes human CD8+ T cell states in cancer","volume":"15","author":"Naulaerts","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2024.217272_bib31","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.1229620","article-title":"Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection","volume":"338","author":"Paley","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.canlet.2024.217272_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111647","article-title":"Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8+ T cell exhaustion and curtails anti-PD-1 efficacy","volume":"41","author":"Chen","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2024.217272_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi8800","article-title":"Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer","volume":"6","author":"Horton","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.canlet.2024.217272_bib34","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1038\/s41467-021-22875-w","article-title":"Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS\/p53 mutant lung cancers","volume":"12","author":"Peng","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.217272_bib35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12032-023-02053-2","article-title":"Depletion of enhancer zeste homolog 2 (EZH2) directs transcription factors associated with T cell differentiation through epigenetic regulation of Yin Yang 1(YY1) in combating non-small cell lung cancer (NSCLC)","volume":"40","author":"Chandnani","year":"2023","journal-title":"Med. Oncol."},{"key":"10.1016\/j.canlet.2024.217272_bib36","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","article-title":"De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation","volume":"170","author":"Ghoneim","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2024.217272_bib37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.217272_bib38","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13059-019-1921-y","article-title":"Distinct epigenetic features of tumor-reactive CD8+ T cells in colorectal cancer patients revealed by genome-wide DNA methylation analysis","volume":"21","author":"Yang","year":"2019","journal-title":"Genome Biol."},{"key":"10.1016\/j.canlet.2024.217272_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.783227","article-title":"The interplay between epigenetic regulation and CD8+ T cell differentiation\/exhaustion for T cell immunotherapy","volume":"9","author":"Wong","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2024.217272_bib40","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/antiox10050802","article-title":"MicroRNAs and oxidative stress: an intriguing crosstalk to Be exploited in the management of type 2 diabetes","volume":"10","author":"Vezza","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.canlet.2024.217272_bib41","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1172\/JCI137585","article-title":"Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells","volume":"130","author":"Yang","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2024.217272_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2018.11.001","article-title":"Modulating ROS to overcome multidrug resistance in cancer","volume":"41","author":"Cui","year":"2018","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2024.217272_bib43","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.3390\/cancers14133123","article-title":"Single B cell gene Co-expression networks implicated in prognosis, proliferation, and therapeutic responses in non-small cell lung cancer bulk tumors","volume":"14","author":"Ye","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.217272_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2022.101703","article-title":"Activation of B cells in tertiary lymphoid structures in cancer: anti-tumor or anti-self?","volume":"65","author":"Fridman","year":"2023","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.canlet.2024.217272_bib45","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1631\/jzus.B2200174","article-title":"Tertiary lymphoid structures as unique constructions associated with the organization, education, and function of tumor-infiltrating immunocytes","volume":"23","author":"Chen","year":"2022","journal-title":"J. Zhejiang Univ. - Sci. B"},{"key":"10.1016\/j.canlet.2024.217272_bib46","article-title":"CD20+CD22+ADAM28+ B cells in tertiary lymphoid structures promote immunotherapy response","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.217272_bib47","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41586-022-05254-3","article-title":"STING-induced regulatory B cells compromise NK function in cancer immunity","volume":"610","author":"Li","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.217272_bib48","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.3389\/fimmu.2018.02456","article-title":"Understanding the multifaceted role of neutrophils in cancer and autoimmune diseases","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.217272_bib49","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.3390\/cancers14163846","article-title":"Circulating low density neutrophils are associated with resistance to first line anti-PD1\/PDL1 immunotherapy in non-small cell lung cancer","volume":"14","author":"Arasanz","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.217272_bib50","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2059876","article-title":"CXCL5-mediated accumulation of mature neutrophils in lung cancer tissues impairs the differentiation program of anticancer CD8 T cells and limits the efficacy of checkpoint inhibitors","volume":"11","author":"Simoncello","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2024.217272_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.785222","article-title":"Neutrophil extracellular traps promote T cell exhaustion in the tumor microenvironment","volume":"12","author":"Kaltenmeier","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.217272_bib52","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1038\/s41467-023-37515-8","article-title":"Smad3 is essential for polarization of tumor-associated neutrophils in non-small cell lung carcinoma","volume":"14","author":"Chung","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.217272_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1261749","article-title":"Tumour-associated macrophages: versatile players in the tumour microenvironment","volume":"11","author":"Ji","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2024.217272_bib54","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41581-019-0110-2","article-title":"Macrophages: versatile players in renal inflammation and fibrosis","volume":"15","author":"Tang","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.canlet.2024.217272_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173090","article-title":"Macrophage M1\/M2 polarization","volume":"877","author":"Yunna","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.canlet.2024.217272_bib56","doi-asserted-by":"crossref","first-page":"eabn5535","DOI":"10.1126\/sciadv.abn5535","article-title":"Single-cell RNA sequencing uncovers a neuron-like macrophage subset associated with cancer pain","volume":"8","author":"Tang","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2024.217272_bib57","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1158\/0008-5472.CAN-18-2545","article-title":"Tumor-associated macrophages enhance tumor hypoxia and aerobic glycolysis","volume":"79","author":"Jeong","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.217272_bib58","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1172\/JCI131335","article-title":"Transcription factor c-Maf is a checkpoint that programs macrophages in lung cancer","volume":"130","author":"Liu","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2024.217272_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1161869","article-title":"Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1\/CTLA-4 immunotherapy resistance","volume":"14","author":"Rodriguez","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.217272_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003890","article-title":"Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1\/PD-L1 antibodies","volume":"10","author":"Larroquette","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2024.217272_bib61","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","article-title":"A conserved dendritic-cell regulatory program limits antitumour immunity","volume":"580","author":"Maier","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.217272_bib62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13046-015-0126-9","article-title":"Anti-CD40-induced inflammatory E-cadherin+ dendritic cells enhance T cell responses and antitumour immunity in murine Lewis lung carcinoma","volume":"34","author":"Zhang","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.217272_bib63","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1158\/0008-5472.CAN-04-0465","article-title":"Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses","volume":"64","author":"Rodriguez","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.217272_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01310","article-title":"Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors","volume":"9","author":"Weber","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.217272_bib65","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/bs.acr.2015.04.002","article-title":"Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment","volume":"128","author":"Parker","year":"2015","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.canlet.2024.217272_bib66","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/0008-5472.CAN-09-2587","article-title":"Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine","volume":"70","author":"Srivastava","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.217272_bib67","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/leu.2012.215","article-title":"Immunosuppressive CD14+HLA-DRlow\/neg Ido+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation","volume":"27","author":"Mougiakakos","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2024.217272_bib68","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2024.217272_bib69","first-page":"1556","article-title":"Myeloid-derived suppressor cells (MDSCs): what do we currently know about the effect they have against anti-PD-1\/PD-L1 therapies?","volume":"17","author":"Tellez","year":"2023","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.canlet.2024.217272_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15586\/jkcvhl.v9i2.208","article-title":"High levels of PD-l1+ and Hyal2+ myeloid-derived suppressor cells in renal cell carcinoma","volume":"9","author":"Kusmartsev","year":"2022","journal-title":"J Kidney Cancer VHL"},{"key":"10.1016\/j.canlet.2024.217272_bib71","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-020-0843-1","article-title":"Myeloid-derived suppressor cells\u2014new and exciting players in lung cancer","volume":"13","author":"Yang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.217272_bib72","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1158\/0008-5472.CAN-20-3564","article-title":"Inhibition of granulocytic myeloid-derived suppressor cells overcomes resistance to immune checkpoint inhibition in LKB1-deficient non-small cell lung cancer","volume":"81","author":"Li","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.217272_bib73","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3390\/cancers13061399","article-title":"The role of cancer-associated fibroblasts in tumor progression","volume":"13","author":"Joshi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.217272_bib74","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1158\/1078-0432.CCR-20-4226","article-title":"Molecular features of cancer-associated fibroblast subtypes and their implication on cancer pathogenesis, prognosis, and immunotherapy resistance","volume":"27","author":"Galbo","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.217272_bib75","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3892\/ol.2021.12674","article-title":"Role of cancer-associated fibroblasts in the resistance to antitumor therapy, and their potential therapeutic mechanisms in non-small cell lung cancer","volume":"21","author":"Chen","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.canlet.2024.217272_bib76","article-title":"Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells","volume":"9","author":"L","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.217272_bib77","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202101230","article-title":"Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade","volume":"5","author":"Miyai","year":"2022","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.canlet.2024.217272_bib78","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1053\/j.gastro.2020.11.011","article-title":"The balance of stromal BMP signaling mediated by GREM1 and ISLR drives colorectal carcinogenesis","volume":"160","author":"Kobayashi","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2024.217272_bib79","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-19-0507","article-title":"Cancer-associated fibroblasts promote immunosuppression by inducing ROS-generating monocytic MDSCs in lung squamous cell carcinoma","volume":"8","author":"Xiang","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2024.217272_bib80","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lungcan.2019.09.013","article-title":"Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer","volume":"137","author":"Teramoto","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2024.217272_bib81","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adh8005","article-title":"Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non\u2013small cell lung cancer","volume":"15","author":"Herzog","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2024.217272_bib82","doi-asserted-by":"crossref","first-page":"e989","DOI":"10.1002\/ctm2.989","article-title":"Cancer-associated fibroblast-derived exosomal microRNA-20a suppresses the PTEN\/PI3K-AKT pathway to promote the progression and chemoresistance of non-small cell lung cancer","volume":"12","author":"Shi","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.canlet.2024.217272_bib83","article-title":"Hematopoietic transcription factor RUNX1 is essential for promoting macrophage-myofibroblast transition in non-small-cell lung carcinoma","author":"Tang","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.canlet.2024.217272_bib84","article-title":"Smad3 promotes cancer-associated fibroblasts generation via macrophage-myofibroblast transition","volume":"9","author":"Tang","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.canlet.2024.217272_bib85","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.ccell.2021.07.004","article-title":"From bench to bedside: single-cell analysis for cancer immunotherapy","volume":"39","author":"Davis-Marcisak","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.217272_bib86","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ccell.2023.01.010","article-title":"Spatial profiling technologies illuminate the tumor microenvironment","volume":"41","author":"Elhanani","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.217272_bib87","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13592","article-title":"Single-cell RNA sequencing to explore cancer-associated fibroblasts heterogeneity: \u201cSingle\u201d vision for \u201cheterogeneous\u201d environment","volume":"57","author":"Zhang","year":"2024","journal-title":"Cell Prolif."},{"key":"10.1016\/j.canlet.2024.217272_bib88","article-title":"Spatially resolved transcriptomics Technology facilitates cancer research","volume":"10","author":"Wang","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.canlet.2024.217272_bib89","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41587-019-0392-8","article-title":"Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas","volume":"38","author":"Moncada","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2024.217272_bib90","article-title":"Single-cell and spatial transcriptomics reveal POSTN+ cancer-associated fibroblasts correlated with immune suppression and tumour progression in non-small cell lung cancer","volume":"13","author":"C","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.canlet.2024.217272_bib91","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1155","article-title":"Multiplex immunofluorescence and single-cell transcriptomic profiling reveal the spatial cell interaction networks in the non-small cell lung cancer microenvironment","volume":"13","author":"Peng","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.canlet.2024.217272_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-01130-8","article-title":"The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing","volume":"7","author":"Wang","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.canlet.2024.217272_bib93","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1038\/s41467-024-48700-8","article-title":"Single-cell and spatial transcriptomics analysis of non-small cell lung cancer","volume":"15","author":"De Zuani","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.217272_bib94","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006343","article-title":"Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor","volume":"11","author":"Gao","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2024.217272_bib95","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s40425-019-0719-5","article-title":"Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells","volume":"7","author":"Mastelic-Gavillet","year":"2019","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/j.canlet.2024.217272_bib96","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.7150\/thno.52435","article-title":"ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation","volume":"11","author":"Chen","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2024.217272_bib97","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/1538-7445.AM2022-601","article-title":"Abstract 601: IO-108, A fully human therapeutic antibody blocking the myeloid checkpoint LILRB2\/ILT4, promotes innate and adaptive anti-cancer immunity in preclinical studies","volume":"82","author":"Ma","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.217272_bib98","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001536","article-title":"Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity","volume":"9","author":"Gao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2024.217272_bib99","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1158\/0008-5472.CAN-20-1885","article-title":"Targeting MARCO and IL37R on immunosuppressive macrophages in lung cancer blocks regulatory T cells and supports cytotoxic lymphocyte function","volume":"81","author":"La Fleur","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.217272_bib100","doi-asserted-by":"crossref","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2024.217272_bib101","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2024.2308097","article-title":"A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance","volume":"25","author":"Santiago-S\u00e1nchez","year":"2024","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canlet.2024.217272_bib102","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrc2355","article-title":"Adoptive cell transfer: a clinical path to effective cancer immunotherapy","volume":"8","author":"Rosenberg","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2024.217272_bib103","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1158\/2326-6066.CIR-16-0293","article-title":"Transfer of allogeneic CD4+ T cells rescues CD8+ T cells in anti-PD-L1-resistant tumors leading to tumor eradication","volume":"5","author":"Arina","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2024.217272_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.canlet.2024.217272_bib105","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00262-011-1020-8","article-title":"Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses","volume":"60","author":"Gameiro","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2024.217272_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101041","article-title":"The promising role of tumor-associated macrophages in the treatment of cancer","volume":"73","author":"Wang","year":"2024","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2024.217272_bib107","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1158\/2326-6066.CIR-22-0547","article-title":"Inhibition of STAT6 with antisense oligonucleotides enhances the systemic antitumor effects of radiotherapy and anti\u2013PD-1 in metastatic non\u2013small cell lung cancer","volume":"11","author":"He","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2024.217272_bib108","doi-asserted-by":"crossref","first-page":"eabd1616","DOI":"10.1126\/scitranslmed.abd1616","article-title":"Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models","volume":"13","author":"Martinez-Usatorre","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2024.217272_bib109","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2241710","article-title":"Effective intravenous delivery of adenovirus armed with TNF\u03b1 and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer","volume":"12","author":"Kudling","year":"2023","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2024.217272_bib110","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg3736","article-title":"Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy","volume":"9","author":"Sarkar","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2024.217272_bib111","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000450","article-title":"PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations","volume":"8","author":"Fabian","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2024.217272_bib112","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1158\/0008-5472.CAN-19-3158","article-title":"NOX4 inhibition potentiates immunotherapy by overcoming cancer-associated fibroblast-mediated CD8 T-cell exclusion from tumors","volume":"80","author":"Ford","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.217272_bib113","doi-asserted-by":"crossref","DOI":"10.1172\/JCI155148","article-title":"Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-\u03b2 signaling enables PD-L1\u2013mediated tumor eradication","volume":"132","author":"Horn","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2024.217272_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100907","article-title":"Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade","volume":"66","author":"Pang","year":"2023","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2024.217272_bib115","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2024.217272_bib116","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","article-title":"Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.217272_bib117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ol.2022.13489","article-title":"Immunosuppressive effects of vascular endothelial growth factor","volume":"24","author":"Ribatti","year":"2022","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.canlet.2024.217272_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100849","article-title":"New insights into antiangiogenic therapy resistance in cancer: mechanisms and therapeutic aspects","volume":"64","author":"Huang","year":"2022","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2024.217272_bib119","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","article-title":"Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses","volume":"55","author":"Banta","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2024.217272_bib120","article-title":"Evaluation of combined pathological responses in primary tumor and lymph nodes following neoadjuvant chemoimmunotherapy in non-small cell lung cancer","volume":"0","author":"Huang","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2024.217272_bib121","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"KEYNOTE-671 investigators, perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.217272_bib122","article-title":"Immunotherapeutic advances for NSCLC","volume":"15","author":"M","year":"2021","journal-title":"Biol. Targets & Ther."},{"key":"10.1016\/j.canlet.2024.217272_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148061","article-title":"Promising immunotherapeutic targets in lung cancer based on single-cell RNA sequencing","volume":"14","author":"Xue","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.217272_bib124","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cels.2023.03.004","article-title":"Uncovering the spatial landscape of molecular interactions within the tumor microenvironment through latent spaces","volume":"14","author":"Deshpande","year":"2023","journal-title":"Cell Syst"},{"key":"10.1016\/j.canlet.2024.217272_bib125","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.bbi.2024.01.223","article-title":"Macrophage is more than a bystander in peripheral sensitisation","volume":"117","author":"Chiu-Tsun Tang","year":"2024","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.canlet.2024.217272_bib126","doi-asserted-by":"crossref","first-page":"9805","DOI":"10.1111\/jcmm.16928","article-title":"AANG: a natural compound formula for overcoming multidrug resistance via synergistic rebalancing the TGF-\u03b2\/Smad signalling in hepatocellular carcinoma","volume":"25","author":"Chung","year":"2021","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.canlet.2024.217272_bib127","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omto.2021.08.010","article-title":"USMB-shMincle: a virus-free gene therapy for blocking M1\/M2 polarization of tumor-associated macrophages","volume":"23","author":"Xue","year":"2021","journal-title":"Mol Ther Oncolytics"}],"updated-by":[{"DOI":"10.1016\/j.canlet.2024.217425","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000}}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524006670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524006670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T04:25:56Z","timestamp":1740371156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524006670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":127,"alternative-id":["S0304383524006670"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217272","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular dynamics of tumor microenvironment driving immunotherapy resistance in non-small-cell lung carcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"217272"}}